Episode 11.2 Rethinking VBAC Risk and a Lot More!

We unpack new studies that reshape how we counsel on VBAC after short intervals, update what we tell BRCA carriers about estrogen therapy, and explore how self-collected HPV tests can reduce screening gaps. We also question surgical marketing, workforce trends, and the shaky evidence behind aspirin dosing for preeclampsia.

• Short interpregnancy interval as a VBAC risk factor, not a contraindication
• Absolute uterine rupture rates in spontaneous vs induced labor
• Estrogen therapy in BRCA carriers and treated gyn cancers
• Cervical screening overuse and underscreening in insured populations
• Self-collected HPV testing intervals and access benefits
• OB-GYN workforce shortages and rural distribution gaps
• Endometriosis surgery indications versus fertility claims
• Robotics versus laparoscopy outcomes and training priorities
• Aspirin dose trials, lack of placebo arms, and abruption signals
• Reading statistics correctly and demanding better editorial standards

0:00Setting The Agenda: New Studies

0:40Short Interval Pregnancy And VBAC Risk

3:10Quantifying Uterine Rupture By Spacing

8:10Induction, Augmentation, And Rupture Math

9:40HRT In BRCA Carriers: New Evidence

13:05Estrogen After Gyn Cancers: Practice Gaps

17:40Cervical Screening: Overuse And Underscreening

22:30Self-Collected HPV Testing Guidance

27:00OB-GYN Shortages And Distribution

33:20Endometriosis Surgery And Fertility Claims

41:20Robotics Vs Laparoscopy: Outcomes And Training

47:20Aspirin Dosing For Preeclampsia: No Signal

55:30Interpreting Stats And Editorial Standards

59:20Closing Notes And Next Steps

Be sure to check out thinking about obgyn.com for more information, and be sure to follow us on Instagram

Follow us on Instagram @thinkingaboutobgyn.